Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02202590 · ClinicalTrials.gov registry record · NA

Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus

A NA study of Eosinophilic Esophagitis, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
96
Enrollment target
1
Study location

NCT02202590 is a NA study of Eosinophilic Esophagitis that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 96 participants, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02202590, a NA study of Eosinophilic Esophagitis, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
96 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to test the feasibility and the tolerability of a tethered spectrally encoded confocal microscopy (SECM) capsule and to use it to image the esophagus.

Conditions Studied

Interventions

  • DEVICE SECM Capsule

Study Locations (1)

Massachusetts

  • Massachusetts General hospital - Boston

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2013-10
Est. Completion 2028-12
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT02202590

The ClinicalTrials.gov registry entry for NCT02202590 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (89% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which SECM Capsule is the first listed.

NCT02202590 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02202590 about?

NCT02202590 is a clinical study titled "Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus". The goal of this study is to test the feasibility and the tolerability of a tethered spectrally encoded confocal microscopy (SECM) capsule and to use it to image the esophagus.

What is the current status of trial NCT02202590?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 96 participants. The study started on 2013-10. Estimated completion is 2028-12.

What conditions does trial NCT02202590 study?

This clinical trial studies the following conditions: Eosinophilic Esophagitis.

What interventions are being tested in trial NCT02202590?

The interventions under investigation include: SECM Capsule (DEVICE).

Who is sponsoring clinical trial NCT02202590?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02202590 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eosinophilic Esophagitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.